Windtree Therapeutics Net Income
| WINT Stock | USD 0.01 0.0006 6.00% |
As of the 27th of February, Windtree Therapeutics maintains the Market Risk Adjusted Performance of (4.45), standard deviation of 10.28, and Mean Deviation of 5.15. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Windtree Therapeutics, as well as the relationship between them.
Windtree Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 706.0804 | Earnings Share 62.6 | Quarterly Revenue Growth (1.00) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -1.6 M | -1.7 M | |
| Net Loss | -2.1 M | -2.2 M | |
| Net Loss | -60.9 M | -63.9 M | |
| Net Loss | (93.91) | (98.61) | |
| Net Income Per E B T | 2.75 | 2.89 |
Windtree | Net Income | Build AI portfolio with Windtree Stock |
The evolution of Net Income for Windtree Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Windtree Therapeutics compares to historical norms and industry peers.
Latest Windtree Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Windtree Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Windtree Therapeutics financial statement analysis. It represents the amount of money remaining after all of Windtree Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Windtree Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Windtree Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (1.79 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Windtree Net Income Regression Statistics
| Arithmetic Mean | (28,499,560) | |
| Coefficient Of Variation | (65.99) | |
| Mean Deviation | 15,338,297 | |
| Median | (27,475,000) | |
| Standard Deviation | 18,807,019 | |
| Sample Variance | 353.7T | |
| Range | 64.8M | |
| R-Value | 0.26 | |
| Mean Square Error | 351.1T | |
| R-Squared | 0.07 | |
| Significance | 0.31 | |
| Slope | 980,603 | |
| Total Sum of Squares | 5659.3T |
Windtree Net Income History
Other Fundumenentals of Windtree Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Windtree Therapeutics Net Income component correlations
Windtree Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Windtree Therapeutics is extremely important. It helps to project a fair market value of Windtree Stock properly, considering its historical fundamentals such as Net Income. Since Windtree Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Windtree Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Windtree Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Windtree introduce new products? Factors like these will boost the valuation of Windtree Therapeutics. Anticipated expansion of Windtree directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Windtree Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Understanding Windtree Therapeutics requires distinguishing between market price and book value, where the latter reflects Windtree's accounting equity. The concept of intrinsic value - what Windtree Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Windtree Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Windtree Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Windtree Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Windtree Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Windtree Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Windtree Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Windtree Therapeutics.
| 11/29/2025 |
| 02/27/2026 |
If you would invest 0.00 in Windtree Therapeutics on November 29, 2025 and sell it all today you would earn a total of 0.00 from holding Windtree Therapeutics or generate 0.0% return on investment in Windtree Therapeutics over 90 days. Windtree Therapeutics is related to or competes with Revelation Biosciences, Dermata Therapeutics, Avenue Therapeutics, XORTX Therapeutics, Virax Biolabs, Ainos, and NewcelX. Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for ... More
Windtree Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Windtree Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Windtree Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.18) | |||
| Maximum Drawdown | 75.0 | |||
| Value At Risk | (20.00) | |||
| Potential Upside | 6.0 |
Windtree Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Windtree Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Windtree Therapeutics' standard deviation. In reality, there are many statistical measures that can use Windtree Therapeutics historical prices to predict the future Windtree Therapeutics' volatility.| Risk Adjusted Performance | (0.11) | |||
| Jensen Alpha | (1.73) | |||
| Total Risk Alpha | (3.20) | |||
| Treynor Ratio | (4.46) |
Windtree Therapeutics February 27, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (4.45) | |||
| Mean Deviation | 5.15 | |||
| Coefficient Of Variation | (613.00) | |||
| Standard Deviation | 10.28 | |||
| Variance | 105.65 | |||
| Information Ratio | (0.18) | |||
| Jensen Alpha | (1.73) | |||
| Total Risk Alpha | (3.20) | |||
| Treynor Ratio | (4.46) | |||
| Maximum Drawdown | 75.0 | |||
| Value At Risk | (20.00) | |||
| Potential Upside | 6.0 | |||
| Skewness | (1.99) | |||
| Kurtosis | 9.0 |
Windtree Therapeutics Backtested Returns
Windtree Therapeutics shows Sharpe Ratio of -0.21, which attests that the company had a -0.21 % return per unit of risk over the last 3 months. Windtree Therapeutics exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Windtree Therapeutics' Market Risk Adjusted Performance of (4.45), mean deviation of 5.15, and Standard Deviation of 10.28 to validate the risk estimate we provide. The firm maintains a market beta of 0.38, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Windtree Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Windtree Therapeutics is expected to be smaller as well. At this point, Windtree Therapeutics has a negative expected return of -1.98%. Please make sure to check out Windtree Therapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Windtree Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.84 |
Very good predictability
Windtree Therapeutics has very good predictability. Overlapping area represents the amount of predictability between Windtree Therapeutics time series from 29th of November 2025 to 13th of January 2026 and 13th of January 2026 to 27th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Windtree Therapeutics price movement. The serial correlation of 0.84 indicates that around 84.0% of current Windtree Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.84 | |
| Spearman Rank Test | 0.52 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Windtree Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Windtree Therapeutics reported net income of (1.79 Million). This is 100.52% lower than that of the Biotechnology sector and 102.55% lower than that of the Health Care industry. The net income for all United States stocks is 100.31% higher than that of the company.
Windtree Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Windtree Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Windtree Therapeutics could also be used in its relative valuation, which is a method of valuing Windtree Therapeutics by comparing valuation metrics of similar companies.Windtree Therapeutics is currently under evaluation in net income category among its peers.
Windtree Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Windtree Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Windtree Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Windtree Therapeutics' value.| Shares | Two Sigma Investments Llc | 2025-03-31 | 0.0 | Xtx Topco Ltd | 2025-03-31 | 0.0 | Activest Wealth Management | 2025-03-31 | 0.0 | Hrt Financial Llc | 2025-03-31 | 0.0 | Jane Street Group Llc | 2025-06-30 | 14.6 K | Tower Research Capital Llc | 2025-06-30 | 2.2 K | Bank Of America Corp | 2025-06-30 | 103 | Sbi Securities Co Ltd | 2025-06-30 | 24.0 | Ubs Group Ag | 2025-06-30 | 22.0 | Goldman Sachs Group Inc | 2025-03-31 | 0.0 | Blackrock Inc | 2025-03-31 | 0.0 |
Windtree Fundamentals
| Return On Equity | -4.13 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | 10.59 M | ||||
| Shares Outstanding | 33.63 M | ||||
| Shares Owned By Institutions | 0.07 % | ||||
| Number Of Shares Shorted | 1.79 M | ||||
| Price To Earning | (0.05) X | ||||
| Price To Book | 0.61 X | ||||
| Price To Sales | 660.53 X | ||||
| Gross Profit | (17.79 M) | ||||
| EBITDA | (1.47 M) | ||||
| Net Income | (1.79 M) | ||||
| Cash And Equivalents | 11.38 M | ||||
| Cash Per Share | 0.37 X | ||||
| Total Debt | 1.82 M | ||||
| Debt To Equity | 0.95 % | ||||
| Current Ratio | 2.47 X | ||||
| Book Value Per Share | 0.39 X | ||||
| Cash Flow From Operations | (15.4 M) | ||||
| Short Ratio | 0.08 X | ||||
| Earnings Per Share | 62.60 X | ||||
| Target Price | 4.0 | ||||
| Number Of Employees | 14 | ||||
| Beta | 0.55 | ||||
| Market Capitalization | 2.02 M | ||||
| Total Asset | 27.88 M | ||||
| Retained Earnings | (846.61 M) | ||||
| Working Capital | (3.14 M) | ||||
| Current Asset | 40.79 M | ||||
| Current Liabilities | 11.07 M | ||||
| Net Asset | 27.88 M |
About Windtree Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Windtree Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Windtree Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Windtree Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Windtree Stock Analysis
When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.